CTSH vs LDOS
Cognizant and Leidos
Cognizant is the larger company at $21B against $13B. On trailing earnings LDOS is the cheaper of the two at a P/E of 11.4 against 12.9, a gap that is only a bargain if the two are growing at similar rates. Over the past year CTSH returned -14% against -34% for LDOS. The RyuScore puts CTSH ahead, 82 against 79 out of 100.
| Figure | CTSH | LDOS |
|---|---|---|
| Last close | $59.19 | $122 |
| Market cap | $21B | $13B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 12.9 | 11.4 |
| Dividend yield | 2.1% | 1.3% |
| 1-year return | -14% | -34% |
| 5-year return | -16% | +32% |
| RyuScoresector-relative, 1–10 | 82/100 | 79/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Cognizant
Revenue of $5.4B in Q1 2026, net income $662M. Its largest reported line is Health Sciences, 32% of the disclosed total.
Leidos
Revenue of $4.6B in Q2 2026, net income $354M. Its largest reported line is Intelligence And Digital, 49% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.